There Are No Useful Monoclonal Antibody Treatments Left Against New COVID Variants
MONDAY, Dec. 5, 2022 (HealthDay News) — The last of six COVID monoclonal antibody treatments has lost its federal authorization because, like the others, it no longer works against the newest Omicron subvariants. This last monoclonal antibody was bebtelovimab, delivered as a one-hour IV infusion. The FDA said in aContinue Reading










